thalidomide has been researched along with Tremor in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, an anti-angiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone." | 9.11 | Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. ( Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A, 2005) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 9.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 5.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "Thalidomide, an anti-angiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone." | 5.11 | Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. ( Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A, 2005) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 5.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 1.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kleber, M | 1 |
| Ihorst, G | 1 |
| Udi, J | 1 |
| Koch, B | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| Morgan, AE | 1 |
| Smith, WK | 1 |
| Levenson, JL | 1 |
| Chiruka, S | 1 |
| Chapman, CS | 1 |
| Cappa, FM | 1 |
| Cantarini, MC | 1 |
| Magini, G | 1 |
| Zambruni, A | 1 |
| Bendini, C | 1 |
| Santi, V | 1 |
| Bernardi, M | 1 |
| Trevisani, F | 1 |
| Neben, K | 1 |
| Moehler, T | 1 |
| Egerer, G | 1 |
| Kraemer, A | 1 |
| Hillengass, J | 1 |
| Benner, A | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Jonsson, BG | 1 |
2 trials available for thalidomide and Tremor
| Article | Year |
|---|---|
Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2005 |
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Topics: Adult; Affect; Aged; Angiogenesis Inhibitors; Constipation; Dizziness; Dose-Response Relationship, D | 2001 |
4 other studies available for thalidomide and Tremor
| Article | Year |
|---|---|
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Dep | 2012 |
Reversible dementia due to thalidomide therapy for multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Dementia; Humans; Male; Multiple Myeloma; Thalidomide; Tremor | 2003 |
Severe tremors associated with use of thalidomide.
Topics: Aged; Female; Humans; Male; Multiple Myeloma; Severity of Illness Index; Thalidomide; Tremor | 2005 |
Effects of thalidomide on the embryonic development of the axolotl (Ambystoma mexicanum).
Topics: Abnormalities, Drug-Induced; Ambystoma; Animals; Cell Differentiation; Cell Division; Edema; Heart R | 1972 |